Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.44 |
| ▸ | CCNC | P24863 | 6/20 | 0.43 |
| ▸ | CDK8 | P49336 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7501979 | 0.84 | HTR1A (0.59) | HTR1AADRA1DADRA1AADRA1BAOC3 | |
| SCHEMBL25395841 | 0.83 | HTR1A (0.49) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL25395839 | 0.83 | HTR1A (0.49) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL6598616 | 0.78 | EGFR (0.63) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL21750424 | 0.75 | CCNC (0.72) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL28216759 | 0.73 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL7622000 | 0.72 | CA9 (0.46) | EGFRPOLBGAAMAPTKMT2A | |
| SCHEMBL4823156 | 0.72 | EGFR (0.43) | HTR1AADRA1DADRA1AADRA1BCCNC | |
| SCHEMBL7501982 | 0.71 | HTR1A (0.65) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL7509055 | 0.71 | HTR1A (0.46) | HTR1AADRA1DADRA1AADRA1BAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348340-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-7189714-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129363-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | CACNA1B, CACNA1E, CACNA1G | HTR1A 400/4885ADRA1D 240/4885ADRA1A 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.